Myriad Genetics Shares Fall Despite Partnership With jscreen
MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.
MYGN Taps Ultima Genomics' UG 100 Platform for Advanced Clinical Tests
Myriad Genetics and Ultima Genomics to explore the latter's sequencing platform for advanced clinical tests in oncology and reproductive genomics.
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Continue to Retain MYGN Stock in Your Portfolio?
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.
Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Myriad Genetics, Inc. (MYGN) Q2 2024 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President-Investor Relations Paul Diaz - President & Chief Executive Officer Mark Verratti - Chief Commercial Officer Sam Raha - Chief Operating Officer Scott Leffler - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Colleen Babington - Wolfe Research Andrew Cooper - Raymond James Casey Woodring - JPMorgan Puneet Souda - Leerink Partners Kyle Boucher - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Second Quarter 2024 Financial Earnings Conference Call.
Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised
Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.
Myriad (MYGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Myriad Genetics (MYGN) Surpasses Q2 Earnings and Revenue Estimates
Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.08 per share a year ago.
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.
